Subscribe Become an Author Add Company Sign Up Log In

Pharmaceutical industry trends


Exyte and Univercells Technologies Combine Аorces for Rapid Deployment of Vaccine Production Plants in the Wake of the COVID-19 Pandemic

   by White Matter Communications    104
  • Exyte offers the new ExyCellR modular technology for fast-track construction of biologicals production facilities compliant with the current good manufacturing practice (cGMP).
  • Univercells Technologies delivers the integrated NevoLine™ biomanufacturing platform, including scale-X™ bioreactors, for low footprint and economic large-scale production of viral products.
  • The combined offer enables users to rapidly deploy prefabricated GMP vaccine manufacturing facilities in response to new disease outbreaks.

Paving A Pathway To Pharma 4.0

   by Cathal Strain    444
Paving A Pathway To Pharma 4.0

Pharmaceutical manufacturers find themselves at a critical juncture. In the past 30 years, pharma has seen some significant shifts. Consider the expanding range of drug therapies, once confined almost exclusively to small molecule drugs. Biologics now comprise a substantial share of the market, and novel treatments such as cell and gene therapies are rapidly gaining traction. Another major trend is the rise of outsourced manufacturing, primarily for small molecule drugs.

The Evolving Pharma R&D Outsourcing Industry: A Bird’s-eye View

   by Andrii Buvailo    2170
The Evolving Pharma R&D Outsourcing Industry: A Bird’s-eye View

Pharmaceutical companies are increasingly outsourcing their R&D activities, including early-stage research programs, to third party organizations -- academic institutions, biotech startups, and private contract research organizations (CROs) -- as a means to stay competitive, flexible, and profitable against all odds.   

Economically, there are factors such as increasing downward pressure on drug pricing by governments, an impending “patent cliff” threatening $198 billion worth of sales during 2019-2024), and downturns in income due to the increasing competition from generics and biosimilars. 

From the innovation's point of view, there is a boom in life sciences, stimulating the emergence of novel biological targets, therapeutic modalities, and even whole new areas of drug discovery -- adding opportunities, but also complexity and uncertainty to research programs. In fact, according to Deloitte’s report, return on late-stage pipelines dropped for the top 12 pharma companies from 10.1% in 2010 down to 3.7% in 2016.

Technologically, there is an unfolding “digital revolution”, bringing even further complexity and investment cost to the table -- in a form of artificial intelligence (AI), data mining and big data technologies, data-driven diagnostics, and digital health. 

Finally, the rise of the personalized medicine paradigm forces companies to rethink their research pipelines and “one-size-fits-all” product development programs, as well as reconsider their market strategies. 

[Interview] The Rise of Quantum Physics in Drug Discovery

   by Andrii Buvailo    2752
[Interview] The Rise of Quantum Physics in Drug Discovery

Computer-aided drug design (CADD) is a central part of so-called “rational drug design”, pioneered in the last century by companies like Vertex. Over the last decades, CADD had great influence on the way new therapeutics are discovered, however, it also showed limitations due to modest accuracy of computational tools.  

The majority of software tools used for computational chemistry and biology rely on molecular mechanics -- a simplified representation of molecules, essentially reducing them down to “balls and sticks”: atoms and bonds between them. In this way it is easier to compute, but accuracy suffers greatly.

In order to gain adequate accuracy, one has to account for the electronic behavior of atoms and molecules, i.e. consider subatomic particles -- electrons and protons. This is what quantum mechanical (QM) methods are all about -- and the theory is not new, dating back to the early decades of the 20th century.  

Annual Summit on Drug Discovery Chemistry

   by BiopharmaTrend    376
Annual Summit on Drug Discovery Chemistry

The Annual Summit on Drug Discovery Chemistry primarily works on the theme “Scientific Congress on pursuit of wisdom in Drug Discovery Chemistry”. The main outcomes of the conference are sharing the insights, experiences and strategies of experts in drug discovery, discover the latest trends in drug chemistry, know the growing demand for drug discovery and pharmaceutical chemistry, find out how progress is being made in scientific formulation in practice and discover the tried and tested bio availability routes.